Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Section Editors
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
RESEARCH LETTER
Frontline inotuzumab ozogamicin in older adults with Philadelphia chromosome-negative B-ALL: an exploratory pooled analysis of efficacy and safety
1
Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China
These authors had equal contribution to this work
Submission date: 2026-08-04
Final revision date: 2026-10-04
Acceptance date: 2026-10-06
Online publication date: 2026-10-21
Corresponding author
Gaoxiang Wang
Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
TOPICS
REFERENCES (16)
1.
Geyer MB, Hsu M, Devlin SM, Tallman MS, Douer D, Park JH. Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis. Blood 2017; 129: 1878-81.
2.
Sive JI, Buck G, Fielding A, et al. Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial. Br J Haematol 2012; 157: 463-71.
3.
Harris EJ, Karaoglu DA, Sukhanova M, et al. Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults. Blood Cancer J 2025; 15: 138.
4.
Chiaretti S, Brugnoletti F, Tavolaro S, et al. TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poor response to induction therapy. Haematologica 2013; 98: e59-61.
5.
Mansor SG, Elgamal R, Saleh MFM, Othman AAA, Nawar SM. Overexpression of TREM1 predicts poor prognosis and chemotherapy resistance in Egyptian acute myeloid leukemia associated with FLT3 internal tandem duplication and CD123 expression and stemness signatures. Discov Oncol 2026; 17: 740.
6.
Song X, Shi F, Wang X, et al. UBC9 silencing-mediated PPAR deSUMOylation induces inhibition of cell proliferation by ferroptosis in acute myeloid leukemia. Arch Med Sci 2026; 22: 1074-83.
7.
Bani-Ahmad MA, Ghanem D. Prognostic value of circulatory growth factors to predict responsiveness to chemotherapy and remission status of patients with acute myeloid leukemia. Arch Med Sci 2024; 20: 1887-93.
8.
Lanza F, Maffini E, Rondoni M, Massari E, Faini AC, Malavasi F. CD22 Expression in B-Cell acute lymphoblastic leukemia: biological significance and implications for inotuzumab therapy in adults. Cancers 2020; 12: 303.
9.
Jabbour EJ, DeAngelo DJ, Stelljes M, et al. Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE. Cancer 2018; 124: 1722-32.
10.
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71.
11.
Stelljes M, Raffel S, Alakel N, et al. Inotuzumab ozogamicin as induction therapy for patients older than 55 years with Philadelphia chromosome-negative B-precursor ALL. J Clin Oncol 2024; 42: 273-82.
12.
Chevallier P, Leguay T, Delord M, et al. Inotuzumab ozogamicin and low-intensity chemotherapy in older patients with newly diagnosed CD22(+) philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. J Clin Oncol 2024; 42: 4327-41.
13.
Kantarjian H, Ravandi F, Short NJ, et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol 2018; 19: 240-8.
14.
Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol 2012; 12: 9.
15.
Kantarjian HM, DeAngelo DJ, Advani AS, et al. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol 2017; 4: e387-98.
16.
Kayser S, Sartor C, Giglio F, et al. Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease. Haematologica 2024; 109: 1385-92.
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
